To determine the impact of tumor biology on rates of breastconserving surgery and pathologic complete response (pCR) after neoadjuvant chemotherapy. Background: The impact of tumor biology on the rate of breast-conserving surgery after neoadjuvant chemotherapy has not been well studied. Methods: We used data from ACOSOG Z1071, a prospective, multicenter study assessing sentinel lymph node surgery after neoadjuvant chemotherapy in patients presenting with node-positive breast cancer from 2009 through 2011, to determine rates of breast-conserving surgery and pCR after chemotherapy by approximated biologic subtype. Results: Of the 756 patients enrolled on Z1071, 694 had findings available from pathologic review of breast and axillary specimens from surgery after chemotherapy. Approximated subtype was triple-negative in 170 (24.5%), human epidermal growth factor receptor 2 (HER2)-positive in 207 (29.8%), and hormone-receptor-positive, HER2-negative in 317 (45.7%) patients. patients with triple-negative (46.8%) and HER2-positive tumors (43.0%) than in those with hormone-receptor-positive, HER2-negative tumors (34.5%) (P = 0.019). Rates of pCR in both the breast and axilla were 38.2% in triplenegative, 45.4% in HER2-positive, and 11.4% in hormone-receptor-positive, HER2-negative disease (P < 0.0001). Rates of pCR in the breast only and the axilla only exhibited similar differences across tumor subtypes. Conclusions: Patients with triple-negative and HER2-positive breast cancers have the highest rates of breast-conserving surgery and pCR after neoadjuvant chemotherapy. Patients with these subtypes are most likely to be candidates for less invasive surgical approaches after chemotherapy.
F
or patients with newly diagnosed, operable breast cancer who have an indication for systemic chemotherapy at the time of presentation based on primary tumor factors, chemotherapy is increasingly given before surgery. [1] [2] [3] [4] The rationale for neoadjuvant chemotherapy is that, in addition to allowing assessment of response to therapy, it can decrease the size or extent of the tumor before surgical resection, decreasing the amount of tissue that needs to be resected and potentially allowing breast-conserving surgery in patients who without such chemotherapy would have required mastectomy. [5] [6] [7] Breast-conserving surgery is considered the preferred approach in early-stage breast cancer, and multiple prospective studies have shown the oncologic safety of breast-conserving surgery followed by adjuvant radiation therapy. [8] [9] [10] [11] [12] [13] Breast-conserving surgery after neoadjuvant chemotherapy has been shown to result in local-regional control rates similar to those in patients undergoing up-front breast surgery. 14 In addition to reducing the size of primary tumors, neoadjuvant chemotherapy can eradicate disease in the regional lymph nodes and can convert node-positive disease to node-negative. Recent studies have shown nodal pathologic complete response (pCR) rates of approximately 40% after neoadjuvant chemotherapy, with some variation based on tumor biologic subtype. [15] [16] [17] The finding of pCR in the breast and axillary lymph nodes after neoadjuvant chemotherapy has been shown in multiple studies to be associated with improved outcomes and is a surrogate marker for survival. 18, 19 Breast cancer is currently classified into biological subtypes with distinct behavior, response to treatment, and outcomes. epidermal growth factor receptor 2 (HER2)] is readily available and can be used to classify tumor types. Approximated biologic subtype is associated with rates of clinical and pathologic response to chemotherapy, but the impact of subtype on surgical procedure has not been well studied.
The American College of Surgeons Oncology Group (ACOSOG) Z1071 study was a prospective clinical trial enrolling patients with node-positive breast cancer receiving neoadjuvant chemotherapy between 2009 and 2011 to evaluate the accuracy of sentinel node surgery. In the study reported here, we sought to determine the impact of tumor biology on rates of breast-conserving surgery as well as on pCR rates in the breast and axillary lymph nodes in patients enrolled on Z1071.
METHODS
ACOSOG Z1071 (clinicaltrials.gov identifier NCT00881361) was a prospective clinical trial enrolling women with histologically proven clinical T0-T4 N1-N2 M0 primary invasive breast cancer who had completed or were planning to undergo neoadjuvant chemotherapy. Patients were enrolled from July 2009 through July 2011. All patients had node-positive disease at presentation confirmed by either fine-needle aspiration biopsy or core needle biopsy of ipsilateral axillary lymph nodes. All patients received chemotherapy before definitive breast and axillary surgery. The current analysis includes all patients who met the protocol eligibility criteria, completed neoadjuvant chemotherapy, and underwent breast and axillary surgery. The institutional review boards of all participating institutions approved the Z1071 study, and written informed consent was obtained from each patient before study entry.
After completion of neoadjuvant chemotherapy, all patients underwent breast and axillary surgery, and surgical specimens were evaluated by a pathologist. The extent of residual disease in the breast and axillary lymph nodes was determined. Operative reports and pathology reports were submitted for central review. Surgical procedure(s) and pathologic response data were entered into a central database.
All patients had estrogen receptor, progesterone receptor, and HER2 status tested on the diagnostic core biopsy sample before neoadjuvant chemotherapy. Approximated biologic subtypes were assigned on the basis of estrogen receptor, progesterone receptor, and HER2 status, which was reported by the treating institution. HER2-positive disease was defined as disease with 3+ HER2 overexpression by immunohistochemistry or HER2 amplification by fluorescence in situ hybridization. Tumors that were negative for estrogen receptor, progesterone receptor, and HER2 were classified as triple-negative; HER2-positive tumors were classified as HER2-positive; and the remaining tumors were classified as hormone-receptor-positive, HER2-negative.
Clinical response to neoadjuvant chemotherapy was determined by comparing the largest single tumor diameter on clinical examination and imaging (mammography, ultrasonography, and magnetic resonance imaging, when performed) at baseline to the largest single tumor diameter on clinical examination and imaging after neoadjuvant chemotherapy. Response was classified according to the Response Evaluation Criteria in Solid Tumors. 23 Complete response was defined as complete or near-complete resolution of the lesion, partial response as a 30% or greater decrease in the size of the lesion, and disease progression as a 20% or greater increase in the size of the lesion; all other responses were defined as stable disease.
Breast surgery was performed within 6 weeks of completion of neoadjuvant chemotherapy. The type of breast surgery was chosen according to surgeon and patient preference and was not mandated by the study protocol. Axillary staging was performed with both sentinel lymph node surgery and completion axillary lymph node dissection.
Pathologic response was calculated using the largest single dimension of the tumor in the surgical specimen. We examined 3 types of pCR: (1) pCR defined according to the most widely used definition-that is, no residual invasive disease in the breast or axilla 19 ; (2) pCR in the breast regardless of axillary response; and (3) pCR in the axilla regardless of breast response.
Statistical Analysis
We evaluated the association of tumor biology, using approximated molecular subtypes, with surgery type and with pCR. Continuous patient and tumor characteristics were compared among the tumor groups with an analysis of variance test or Kruskal-Wallis test, whichever was more appropriate. In the case of comparisons between 2 groups, a 2-sample t test or rank-sum test, whichever was appropriate, was used. Categorical variables were compared among/between groups using a χ 2 test. To determine factors associated with breastconserving surgery after neoadjuvant chemotherapy, univariable and multivariable logistic regression models were used. Point estimates and 95% confidence intervals of the odds ratios are presented. All tests were 2-sided, and a P < 0.05 was considered statistically significant. The database used for these analyses was locked on April 8, 2014. The statistical analyses were performed by the Alliance Statistics and Data Center using SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS

Patient Characteristics
Seven hundred fifty-six patients with T0-T4 N1-N2 M0 breast cancer across 136 institutions were enrolled in the ACOSOG Z1071 study. Twenty-one women were ineligible and 34 withdrew from the study before surgery. Six hundred ninety-four patients were eligible and had findings available from pathology review of breast and axillary specimens from surgery after neoadjuvant chemotherapy. These 694 patients made up the cohort for this study. Approximated tumor subtype was triple-negative in 170 (24.5%) patients, HER2-positive in 207 (29.8%) patients, and hormone-receptor-positive, HER2-negative in 317 (45.7%) patients. Baseline patient and tumor characteristics for the 694 patients by tumor subtype are shown in Table 1 . Patient age, clinical T stage, tumor size at presentation, and clinical nodal stage at presentation (N1 vs N2) did not differ across the subtypes.
For the study group overall, the median tumor diameter was 4.0 cm (range, 0.8-15.0 cm). The majority of patients had T2 tumors (55%), and 59% of patients had tumors 4 cm or larger in diameter. Chemotherapy regimens included both an anthracycline and a taxane in 520 patients (74.9%), a taxane but not an anthracycline in 119 patients (17.2%), an anthracycline but not a taxane in 43 patients (6.2%), and other regimens in 12 patients (1.7%). Of the 207 patients with HER2-positive disease, 184 (88.9%) received trastuzumab with their neoadjuvant chemotherapy.
Breast Surgery
Overall, 60.0% of patients underwent mastectomy, and 40.0% underwent breast-conserving surgery ( Table 2 ). The rates of breastconserving surgery were higher in patients with triple-negative and HER2-positive breast cancer (46.8% and 43.0%, respectively) than in patients with hormone-receptor-positive, HER2-negative disease (34.5%; P = 0.019) ( Table 2 , Fig. 1 ).
The overall reoperation rate was 7.3%. The reoperation rate was significantly higher in patients with hormone-receptor-positive, HER2-negative disease (9.8%) than in patients with triple-negative or HER2-positive disease (3.5% and 6.8%, respectively; P = 0.039). Of the 51 patients who required more than 1 breast operation, 31 patients (60.8%) underwent reexcision of the lumpectomy cavity and completed breast conservation, 14 patients (27.5%) converted from breast-conserving surgery to mastectomy, and 6 patients (11.8%) had reexcision of a margin after initial mastectomy. Within the group of patients with hormone-receptor-positive, HER2-negative disease, the requirement for more than 1 breast operation was significantly higher in lobular tumors than in ductal tumors (25% vs 9%, P = 0.044). Breast-conserving surgery was more common in patients who presented with T0-T2 tumors than in those who presented with T3-T4 tumors (Table 3 ). However, 52% of patients who presented with clinical T0-T2 disease underwent mastectomy. Of the patients who presented with clinical T3-T4 disease, 23% underwent breastconserving surgery. Reoperation after initial breast-conserving surgery was more common in patients with T2/T3 tumors than in those with T0/T1 tumors.
Predictors of Successful Breast Conservation
The univariable and multivariable evaluation of factors associated with rates of successful breast conservation included patient age, clinical T stage at presentation, and tumor subtype (Table 4) . On univariable analysis, variables associated with a higher likelihood of breast conservation were older age, lower T category at presentation, and HER2-positive and triple-negative tumor subtypes.
On multivariable analysis, older age, lower tumor stage at presentation, and HER2-positive and triple-negative tumor subtypes (P = 0.04) remained significant predictors of breast conservation (Table 4) .
Clinical Breast Tumor Response to Neoadjuvant Chemotherapy
Clinical assessment of changes in tumor size in the breast between baseline and completion of neoadjuvant chemotherapy showed that 166 patients (27.4%) had a complete response, 329 (54.2%) had a partial response, 79 (13.0%) had stable disease, and 33 (5.4%) had disease progression. These clinical response rates appeared to be similar across all tumor subtypes (P = 0.42) ( Table 2) . Clinical tumor size after neoadjuvant chemotherapy was also similar across all tumor subtypes (P = 0.12) ( Table 2 ).
Pathologic Breast Tumor Response to Neoadjuvant Chemotherapy
Overall, pathologic response rates in the breast were as follows: complete response, 33.8%; partial response, 46.1%; stable disease, 13.9%; and disease progression, 6.2% (Table 2) . The breast pCR rates were significantly higher in patients with triple-negative tumors and HER2-positive tumors (47.9% and 50.2%, respectively) than in patients with hormone-receptor-positive, HER2-negative tumors (15.5%; P < 0.0001). In addition, among patients with residual disease, pathologic tumor size after neoadjuvant chemotherapy was larger in patients with hormone-receptor-positive, HER2-negative disease than in patients with the other tumor subtypes (P = 0.026). hormone-receptor-positive, HER2-negative disease (Fig. 2 ). Among patients with residual nodal disease, the mean number of positive nodes was higher in patients with hormone-receptor-positive, HER2-negative disease (5.0 nodes) than in those with triple-negative and HER2-positive disease (3.5 nodes and 3.3 nodes, respectively; P = 0.001). Although the size of the largest residual lymph node metastasis in patients with residual positive nodes differed across tumor subgroups (Table 2) , this difference did not achieve statistical significance (P = 0.06).
Rates of pCR in the Breast and Axilla
Overall, the rate of pCR in both the breast and axilla was 28%. The rate of pCR in the breast and axilla was significantly higher in patients with triple-negative disease and HER2-positive disease (38.2% and 45.4%, respectively) than in those with hormonereceptor-positive, HER2-negative disease (11.4%; P < 0.0001).
DISCUSSION
Determination and stratification of breast cancer by molecular subtypes has improved understanding and treatment of the disease. The subtype influences the choice of chemotherapeutic agent, response to chemotherapy, and risk of recurrence. In this retrospective review of data from a prospective multicenter study of 694 women treated with neoadjuvant chemotherapy, we found that approximated tumor subtype was associated with type of surgical procedure after neoadjuvant chemotherapy as well as with the pathologic response in the breast and regional nodes. Specifically, patients with triplenegative or HER2-positive breast cancer were more likely to undergo breast-conserving surgery and more likely to achieve a pCR. The response rates to neoadjuvant chemotherapy in this study are in keeping with those in prior studies, which have shown that pCR rates in the breast and lymph nodes are higher in patients with triple-negative or HER2-positive disease. For triple-negative tumors, the reported rates of pCR in the breast and axilla include 35.8% in the German Breast Group pooled analysis, 35% in the ISPY1 trial, and 38% in a report from The University of Texas MD Anderson Cancer Center, similar to the rate of 38% seen in this study. 15, 24, 25 In addition, all patients on Z1071 had node-positive disease, whereas the other studies mentioned had a mixture of clinically node-negative and node-positive disease at presentation, which accounts for some of the differences in pCR rates reported here.
The rate of pCR in the breast and axilla for patients with HER2-positive tumors in the current study was 45%. This is similar to the 48.3% and 46.7% rates of breast and axillary pCR seen in the ACOSOG Z1041 study. 26 For HER2-positive tumors, the German pooled analysis reported pCR rates of 32% in luminal B/HER2-positive and 51% in nonluminal HER2-positive disease treated with trastuzumab. 15 The ISPY1 investigators reported a pCR rate of 54% in patients with HER2-positive disease; however, this was based on only 13 patients. 24 The fact that not all patients with HER2-positive tumors in the Z1071 trial received trastuzumab with their chemotherapy Copyright © 2014 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. may account for some of the differences between our study and prior studies regarding pCR rates in patients with HER2-positive disease.
In this study, we found a breast conservation rate of 43% in women with HER2-positive breast cancer, which is higher than rates in the NOAH study, in which 23% of patients with HER2-positive disease who were treated with neoadjuvant trastuzumab from 2002 to 2005 completed breast-conserving surgery, compared to 13% of those who did not receive trastuzumab. 27 Our rate of 43% is similar to the 38% rate of breast-conserving surgery in HER2-positive patients in the Z1041 trial, in which surgery type was also dictated by surgeon and patient preference. 26 We found that the pCR rate in patients with hormone-receptorpositive, HER2-negative disease was only 11%, which is similar to the previously reported pCR rates of 9% in ISPY1 24 and of 8.9% in luminal A and 15.4% in luminal B/HER2-negative disease in the German studies. 15 In a series from MD Anderson Cancer Center, the pCR rate in patients with hormone-receptor-positive, HER2-negative disease was only 9%. These patients had excellent local recurrence-free survival regardless of tumor response to neoadjuvant chemotherapy, reflecting the overall favorable biology of hormonereceptor-positive disease and the effectiveness of endocrine therapy. 25 The German pooled analysis showed that pCR correlates with survival in estrogen-receptor-negative, HER2-positive disease and triplenegative disease but not in luminal tumors. 15 Although lower rates of pCR to neoadjuvant chemotherapy in patients with hormonereceptor-positive, HER2-negative tumors have been previously reported, this study is one of the first to show lower rates of breastconserving surgery in these patients. The ACOSOG Z1031 trial prospectively evaluated patients with estrogen-receptor-positive disease and demonstrated that neoadjuvant endocrine therapy could decrease tumor size, such that 65% of patients thought to be marginal candidates for breast conservation and 38% of patients thought to be ineligible for breast conservation were able to preserve their breast. 28 For patients with luminal A tumors, neoadjuvant endocrine therapy may be more likely to provide reduction in tumor size and successful breast conservation than neoadjuvant chemotherapy.
Because our study was a retrospective analysis of data from a prospective clinical trial, we do not know how many patients were not candidates for breast-conserving surgery at initial presentation but were converted to breast conservation as a result of neoadjuvant chemotherapy. However, in this study, 23% of women who presented with T3-T4 tumors had breast conservation, and it is likely that neoadjuvant chemotherapy altered their surgical options as it would be anticipated that most women with T3-T4 tumors (tumors larger than 5 cm) would require mastectomy. This is similar to the National Surgical Adjuvant Breast and Bowel Project B-18 study in which for patients with tumors 5 cm or larger, lumpectomy was proposed at presentation in 3% but performed in 22% after neoadjuvant chemotherapy. 29 In addition, because of the retrospective nature of our study, we do not know how many women were potential candidates for breast conservation after neoadjuvant chemotherapy but elected mastectomy. However, 52% of patients with clinical T0-T1 disease at presentation elected mastectomy after chemotherapy, and as rates of disease progression were very low, this finding suggests that overall, significantly more women were candidates for breast conservation than elected breast conservation.
Another limitation of our study is the use of approximated tumor subtype and inability to separate the hormone-receptor-positive, HER2-negative tumors into luminal A and luminal B as we did not perform gene profiling. Furthermore, because of the small sample size, we did not separate the HER2-positive tumors by hormone receptor status. This is one of a few studies to evaluate the impact of tumor subtype on surgical procedure. This information is important when setting patient expectations at the initiation of chemotherapy and can guide patient education as well as the selection of surgical procedure after completion of chemotherapy. Our findings indicate that women with HER2-positive disease or triple-negative disease have a high likelihood of pCR and are more likely to successfully complete breast-conserving surgery. However, women with hormone-receptorpositive, HER2-negative disease are significantly less likely to achieve a pCR and in this study had a higher rate of mastectomy. This may be explained by the higher proportion of lobular tumors in the hormonereceptor-positive, HER2-negative group, as the lobular tumors in this group had higher rates of second breast procedures compared with the ductal tumors in the same subgroup.
The differences in breast surgery observed in this study reflect the surgical choice of patients and their treating surgeons. Almost half the patients who achieved a pathological complete response elected to undergo mastectomy. Perhaps this identifies an opportunity to improve patient counseling and surgeon education regarding the option of breast conservation surgery after neoadjuvant chemotherapy. Although pathologic complete response rates did vary by tumor type, pCR is not a prerequisite for breast conservation and clinical tumor sizes were not different across the approximated tumor type groups. We are not recommending that patients with hormone-receptorpositive, HER2-negative disease are discouraged from breast conservation when clinical response is appropriate for breast conservation.
In addition to decreasing the size of the primary tumor, neoadjuvant chemotherapy is effective in reducing the burden of disease in the regional lymph nodes. Our findings show that the likelihood of conversion from node-positive to node-negative disease is higher in women with HER2-positive or triple-negative breast cancer than in those with hormone-receptor-positive, HER2-negative disease and that the overall residual nodal burden is higher in hormone-receptorpositive, HER2-negative disease. Neoadjuvant chemotherapy provides opportunities to minimize the extent of surgery both to the breast and to the axilla. With conversion of node-positive disease to node-negative, axillary staging with sentinel lymph node surgery allows patients who have converted to node-negative to potentially avoid axillary lymph node dissection.
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CONCLUSIONS
Patients with triple-negative or HER2-positive breast cancer achieve the highest rates of breast-conserving surgery and pCR after neoadjuvant chemotherapy (when trastuzumab is included for HER2-positive tumors). Patients with these tumor subtypes are more likely to be candidates for less invasive surgical approaches after neoadjuvant chemotherapy.
DISCUSSANTS H. Bear (Richmond, VA):
These data confirm results from multiple previous studies, showing that hormone-responsive breast cancers are less likely to respond to chemotherapy than hormone-receptor-negative cancers. In this study, the subsets are not true molecular intrinsic subtypes but were based on commonly available markers. As expected from the fact that these patients were all node-positive at the time of diagnosis, the distribution is skewed somewhat toward the more aggressive subtypes than the average cohort of breast cancer patients.
Comparing the pathologic complete response rate for breast and nodes from this study with other studies must be interpreted especially cautiously because this cohort includes only patients with proven nodal metastases, whereas most other studies include a mix of node-negative and node-positive subjects.
Frankly, I have always been a bit skeptical of calling histologically negative nodes after neoadjuvant chemotherapy "complete responses" when it was not known that the nodes contained any cancer to begin with. Despite the limited sample size, it would have been very interesting to sort out the estrogen-receptor (ER)-positive and ER-negative subsets of HER2-amplified cancers, because others have found that luminal HER2-positive cancers are less responsive to chemotherapy, even with trastuzumab. Moreover, pathologic complete responses for luminal HER2-positive cancers may not predict better outcomes.
Similarly, it would have been interesting to compare basal versus nonbasal triple-negative breast cancers because these also differ in response rates and outcomes. These issues highlight how important it has become to collect tissue samples prospectively in clinical trials, which is one reason for the importance of surgeons being involved in these studies.
It is clear from this study that pathologic complete response is not a useful endpoint for chemotherapy for most luminal breast cancers. Combined with the results of ACOSOG Z1031, the data suggest that hormonal therapy may be a better choice for some of these patients. However, the pathologic complete response rate for hormonal therapy is nearly zero. So, for hormone-responsive breast cancers, the goal should be a clinically useful response and not necessarily a pathologic complete response. We are currently conducting a pilot trial that examines the use of gene expression profiling to help decide between chemotherapy and hormonal therapy for hormone-receptorpositive cancers in the neoadjuvant setting.
I have several questions for the authors. Did the authors attempt to define the response rates for an approximation of the luminal B subset by analyzing hormone-receptorpositive cancers that were high grade or had high Ki-67?
Second, as you suggested in one of your conclusions, will these patients be followed long-term to determine whether there are differences in the correlation of pathologic complete response with outcomes for different subsets?
Finally, why do the authors think that the breast conservation rate was significantly lower for hormone-receptor-positive HER2-negative cancers, even though the clinical tumor sizes after treatment were only very slightly larger than the other 2 subsets? Were the mastectomies in these patients really necessary?
Interestingly, the median tumor size in this study was similar to the median tumor size in NSABP B-18 and B-27, but the breast conservation rate in both of those studies was well over 60%, compared to just 41% for T1 to T3 tumors in this study.
So, why has breast conservation after neoadjuvant chemotherapy not caught on and are rates actually declining? Does this result from a lack of understanding of what is happening biologically by both surgeons and their patients, or is it just a function of increased consumer demand for mastectomies?
Response From J. Boughey:
In response to your first question regarding subdividing the luminal B subtype, we did not collect Ki-67 data on these patients. Most of these centers were not routinely performing Ki-67 in that time period. However, we were able to separate this into 2 subgroups based on grade: low-and intermediate-grade tumors and high-grade tumors. It would not be surprising to hear that the patients with lowand intermediate-grade tumors had a much lower rate of pathologic complete response in the breast (5%) than those with high-grade tumors (5% vs 30%, P < 0.001). Interestingly, the breast conservation rate was slightly higher in the high-grade group at 39%, compared to 31% in the low-and intermediate-grade group; however, this did not reach statistical significance.
You also alluded to the same question about the patients with HER2-positive tumors and separating them on the basis of hormone receptor status. Similar trends were seen here, with the patients having higher pathological complete response rates in the breast with ERand PR-negative tumors, compared to those with ER-or PR-positive tumors (63% vs 41%, P = 0.002). The breast conservation rate was not statistically significantly different at 47% for ER/PR-negative, HER2-positive cases and 40% for ER/PR-positive, HER2-positive cases (P = 0.34).
The plan is to follow patients enrolled on ACOSOG Z1071 for 10 years. So, we do hope that we will have at least 5-year outcome data on these patients available to us, probably around 2016, and hopefully also 10-year data.
With respect to your third question regarding the mastectomy rates, that's a great question. There are definitely patients in this cohort who may have undergone a mastectomy who had a complete pathologic response in the breast. The debate surrounding the issue of unnecessary mastectomy is a topical one and we could probably take up the rest of the afternoon with that discussion. Nationwide, regardless of the use of neoadjuvant chemotherapy, multiple centers have shown that the rates of breast conservation, which initially increased in the 1990s, have recently been on the decline. In parallel, obviously, the rates of mastectomy are on the rise. So, it's very hard to comment whether this is a failure of breast conservation after neoadjuvant chemotherapy or just a decline overall in breast conservation surgery.
C. Lucas (Detroit, MI):
In your HER2 patients who have complete response, is there any role for nonsurgical observation similar to what we do with squamous cancer of the anus?
Response From J. Boughey:
That's an excellent question. I think that's a question that several groups are considering-as to whether we can look at avoiding surgical resection in patients who achieve a pathologic complete response, especially in the HER2-positive cancers where we are being so successful with systemic treatment and witnessing increasing rates of pathologic complete response. One of the limitations in this field is having the ability to accurately predict cases with a pathological complete response based on imaging or other methods. So, currently, surgery remains at the forefront. But I think, as we develop better imaging modalities, if we can be more comfortable in predicting the pathologic findings, there will be future trials looking at avoiding surgical resection in cases thought to have a complete response.
C. Grant (Rochester, MN):
In light of these and other data, for patients with hormonereceptor-positive, HER2-negative, low grade or low Ki-67 disease, should neoadjuvant endocrine therapy rather than chemotherapy be used, given your data showing marginal pathologic response in these patients.
Response From J. Boughey:
Yes, in those patients where, on the basis of tumor biology, we believe that their greatest benefit is from endocrine therapy, we are increasingly looking at treating those patients with neoadjuvant endocrine therapy. I think some of our challenges have been in the clinical setting differentiating the luminal tumors into those that are relatively endocrine resistant and would still benefit from chemotherapy from those that will get the majority of their benefit from endocrine therapy. There are newer approaches such as the ALTER-NATE Trial where patients receive neoadjuvant endocrine therapy and then undergo biopsy on endocrine treatment to evaluate the change in the proliferation rate. If the proliferation rate after exposure to endocrine therapy is below a specific cutoff value, patients will remain on the same therapy, whereas those in whom the proliferation rate is higher than the cutoff will be switched to chemotherapy. This may be a very good strategy to allow us to move forward in this field.
B. Smith (Boston, MA):
Many of the patients who are ER-positive in this trial may have had invasive lobular carcinomas, which are often larger tumors at diagnosis and have a notoriously poor response with any kind of neoadjuvant therapy. I wonder if your data tell you how much lobular histology accounts for results.
The second point is that none of the studies of neoadjuvant therapy versus surgery first have shown any survival benefit from the order in which the treatments are given. So, we mainly use neoadjuvant therapy if we are trying to study a question, study a new drug, or if we think we can achieve breast conservation where we hadn't been able to before, or, obviously, for very advanced patients who aren't operable. 
